Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma

Prior to 2011, the 1-year survival rates for patients suffering from advanced or metastatic melanoma was as low as 33%, with a median overall survival of about 9 months. Several chemotherapeutic regimens have been applied, either as monochemotherapy or as polychemotherapy, overall not resulting in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Banzi, Maria, De Blasio, Simona, Lallas, Aimilios, Longo, Caterina, Moscarella, Elvira, Alfano, Roberto, Argenziano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866744/
https://www.ncbi.nlm.nih.gov/pubmed/27226731
http://dx.doi.org/10.2147/OTT.S75104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866744/
https://www.ncbi.nlm.nih.gov/pubmed/27226731
http://dx.doi.org/10.2147/OTT.S75104

Ejemplares similares